Utilize este identificador para referenciar este registo: http://hdl.handle.net/10400.16/2252
Registo completo
Campo DCValorIdioma
degois.publication.firstPage211pt_PT
degois.publication.issue3pt_PT
degois.publication.lastPage232pt_PT
degois.publication.locationPortugalpt_PT
degois.publication.titlePortuguese Journal of Nephrology and Hypertensionpt_PT
dc.relation.publisherversionhttp://www.spnefro.pt/rpnh/browse_all_issues/69_volume_32_number_3pt_PT
dc.contributor.authorAzevedo, A.-
dc.contributor.authorFaria, B.-
dc.contributor.authorTeixeira, C.-
dc.contributor.authorCarvalho, F.-
dc.contributor.authorNeto, G.-
dc.contributor.authorSantos, J.-
dc.contributor.authorSantos, M.-
dc.contributor.authorOliveira, N.-
dc.contributor.authorFidalgo, T.-
dc.contributor.authorCalado, J.-
dc.date.accessioned2018-11-06T11:00:11Z-
dc.date.available2018-11-06T11:00:11Z-
dc.date.issued2018-
dc.identifier.citationPort J Nephrol Hypert 2018; 32(3): 211-232pt_PT
dc.identifier.issn2183-1289-
dc.identifier.urihttp://hdl.handle.net/10400.16/2252-
dc.description.abstractAmong thrombotic microangiopathies (TMA), the hemolytic uremic syndrome associated with dysregulation of the alternative complement pathway (aHUS) is one of the most challenging diseases a nephrologist can face. By the end of the XXth century, the complement’s role was unraveled with the discovery that mutations in the factor H coding gene were responsible for aHUS. But it was the acknowledgment that pharmacological C5-9 blockage provided a cure for aHUS that fostered the interest of the nephrology community in the genetics, pathophysiology and therapeutics of, not only of aHUS, but TMA in general. The molecular genetics of aHUS is technically demanding and, as such, in Portugal (alike many other European countries) a single laboratory emerged as a national reference center. The fact that all samples are evaluated in a single center provides a unique opportunity for data collection and a forum for discussion for all those interested in the field: immunologists, molecular geneticists, pathologists and nephrologists. The current consensus document emerged from such a discussion forum and was sponsored by the Portuguese Society of Nephrology. The goal is more to portray the Portuguese picture regarding the diagnostic approach and therapeutic options than to extensively review the state of the art of the subject. The accompanying documents that are published as supplementary data are in line with that goal. They range from the informed consent and clinical form to be sent together with the biological samples for genetic testing, to the appendix regarding the actual sampling and storing conditions. The document is also intended to set an example for future documents and independente discussion forums on other kidney diseases for which emerging diagnostic and/or therapeutic strategies are reaching clinical practice.pt_PT
dc.language.isoengpt_PT
dc.publisherSociedade Portuguesa de Nefrologiapt_PT
dc.rightsopenAccesspt_PT
dc.subjectatypical hemolytic uremic syndromept_PT
dc.subjectdiagnosis,pt_PT
dc.subjectkidney transplantationpt_PT
dc.subjectterminal complement blockagept_PT
dc.titlePortuguese consensus document statement in diagnostic and management of atypical hemolytic uremic syndromept_PT
dc.typearticlept_PT
dc.description.versioninfo:eu-repo/semantics/publishedVersionpt_PT
dc.peerreviewedyespt_PT
degois.publication.volume32pt_PT
Aparece nas colecções:SNEF - Artigos publicados em revistas não indexadas na Medline

Ficheiros deste registo:
Ficheiro Descrição TamanhoFormato 
Portuguese consensus document.pdf980,8 kBAdobe PDFVer/Abrir


FacebookTwitterDeliciousLinkedInDiggGoogle BookmarksMySpace
Formato BibTex MendeleyEndnote Degois 

Todos os registos no repositório estão protegidos por leis de copyright, com todos os direitos reservados.